- Home
- RPRX vs ES Comparison
RPRX vs ES Comparison
Compare RPRX & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | ES |
|---|---|---|
| Founded | 1996 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 25.1B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RPRX | ES |
|---|---|---|
| Price | $54.87 | $68.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 11 |
| Target Price | $51.40 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 3.3M | 2.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 1.90% | ★ 4.58% |
| EPS Growth | N/A | ★ 100.88 |
| EPS | 0.67 | ★ 1.61 |
| Revenue | $2,378,193,000.00 | ★ $13,547,244,000.00 |
| Revenue This Year | $38.63 | N/A |
| Revenue Next Year | $4.73 | $3.77 |
| P/E Ratio | $82.49 | ★ $42.52 |
| Revenue Growth | 5.06 | ★ 13.83 |
| 52 Week Low | $34.39 | $61.53 |
| 52 Week High | $56.50 | $76.41 |
Technical Indicators
Market Signals| Indicator | RPRX | ES |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 47.61 |
| Support Level | $35.35 | $66.23 |
| Resistance Level | N/A | $68.84 |
| Average True Range (ATR) | 1.31 | 1.54 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 50.00 | 35.12 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.